RESEARCH TRIANGLE PARK, N.C., Oct. 8 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of Jay D. Norman to serve as President of its expanding Quintiles Consulting business, which helps pharmaceutical, biotech and medical device companies maximize potential and minimize risk from early discovery through commercialization.
Quintiles is investing in the growth of its consulting business to help meet the needs of its customers as they face increasingly complex regulatory, development and market challenges. Building on its current practice areas and the global reach and expertise of its parent company, Quintiles Consulting's offerings will encompass strategic product development, regulatory compliance, and pricing and reimbursement.
"As the world's largest CRO, Quintiles is uniquely positioned to provide our consulting clients with competitive advantages and insight as they navigate the development process and look to expand the financial and therapeutic potential of their products," said John Ratliff, Quintiles Transnational Chief Operating Officer. "With Jay's experience in developing consultancies, and the industry and former FDA experts we already have on staff, Quintiles is poised to expand its footprint in the consulting arena."
Norman brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer. Norman's accomplishments at Diamond earned him recognition by Consulting Magazine, which named him a "Top 25 Consultant" in 2006. Norman's diverse background also includes positions of increasing leadership responsibility at top firms such as PricewaterhouseCoopers Consulting, McKinsey and Company, Inc. and Accenture.
"Quintiles Consulting is already recognized for its outstanding client service and insight in providing practical solutions to regulatory challenges," Norman said. "With the strategic investment Quintiles is making in consulting services and the reputation we have from our existing practices, we are well-positioned to become the premier global provider of strategic consulting to the life sciences industry."
Quintiles Consulting has consultants based across the U.S. and Europe to serve its global clients.
About Quintiles Transnational
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With 19,000 employees and offices in more than 50 countries, it is focused on providing customers with solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.qtrn.com.
CONTACT: Rachael Tarleton Fones, Media Relations, +1-919-998-2136,
media.info@quintiles.com, or Greg Connors, Investor Relations,
+1-919-998-2000, invest@quintiles.com, both of Quintiles Transnational
Corp.
Web site: http://www.qtrn.com/
